TERT PROMOTER MUTATION AS A POTENTIAL PREDICTIVE BIOMARKER IN BCG-TREATED BLADDER CANCER PATIENTS
Sunday, March 13th, 2022
Recently, investigators described in a scientific publications in a recognized international journal (International Journal of Molecular Sciences), the future possibility of the use of an genetic alterations in TERT gene, included in the Uromonitor test, to be used as a therapy response predictive biomarker in BCG treatment.
The details of this study can be found at: